Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
New treatments are reshaping who manages thyroid eye disease. With FDA approvals of teprotumumab (2020) and veligrotug (2026), endocrinologists are now well-positioned to screen, diagnose, and treat the condition early — rather than defaulting to ophthalmologists. A new commentary argues endocrinologists should serve as the "clinical anchor," coordinating multidisciplinary care to cut the current 3–5 year diagnostic delay.
For years, thyroid eye disease (TED) was largely handed off to ophthalmologists — and for good reason. With limited medical options beyond steroids, surgery was often the only real intervention. But the treatment landscape has shifted dramatically, and endocrinologists may need to rethink their role.
Writing in AACE Endocrinology and Diabetes, Dr. Thanh D. Hoang argues that endocrinologists should now serve as the "clinical anchor" for TED management. Since TED occurs predominantly in patients with Graves' disease — who are already under endocrine care — endocrinologists are uniquely positioned to catch the disease early, initiate disease-modifying therapy, and coordinate a multidisciplinary team including ophthalmologists, oculoplastic surgeons, and radiation oncologists.
Key Takeaways:
Why it matters: Earlier diagnosis and coordinated care can meaningfully improve outcomes for TED patients. With powerful new therapies now available, the window for effective treatment is real — but only if clinicians act before the disease progresses.
